



Interdisciplinary Advances in Health, Environment, and Biotechnology: From Pandemic Insights to Sustainable Therapeutics

Bashaer Khairi¹ Muhammad Akram^{2*}

²Department of Biological Sciences, College of Science, Tikrit University

²Department of Eastern Medicine, Government College University Faisalabad-Pakistan

E-mail: makram_0451@yahoo.com

*Email corresponding author's: makram_0451@yahoo.com

Received:3/1/2026

Accepted:31/1/2026

Published:2/2/2026

Abstract

The COVID-19 pandemic has underscored the deep links between public health, environmental change, and biotechnology. This paper reviews recent interdisciplinary research at the nexus of these domains. We examine pandemic-era insights into mental health, disease biomarkers, and vaccine development. We explore how environmental challenges from climate-driven disease dynamics to sustainable agriculture intersect with human health. Advances in biotechnology, including AI-driven drug discovery, gene editing, and bio-based therapeutics, are highlighted for their roles in building resilience. We also discuss practical data sources and experiments, such as global health and climate datasets, that inform policy and treatment strategies. This review links findings on chronic diseases, infectious threats, and environmental sustainability. Key topics include mental health impacts of COVID-19 (e.g. anxiety and depression prevalence), antimicrobial resistance trends, and innovative therapies (e.g. nanomedicine, plant-derived drugs). The synthesis underscores the need for One Health approaches that integrate medical, ecological, and technological solutions. Our findings suggest that combating future pandemics and achieving sustainable health outcomes will rely on cross-disciplinary collaboration, data-driven policies, and green biotechnologies.

Keywords: COVID-19, climate change, biotechnology, mental health, sustainable agriculture, antimicrobial resistance, vaccines, one health.

Doi : <https://doi.org/10.64943/ljacs.2026.010102>

INTRODUCTION

The COVID-19 crisis has shown that human health is deeply connected to environmental and technological factors. Research has documented wide-ranging pandemic impacts: psychological stress increased globally, especially among vulnerable groups [1], and routine healthcare (e.g. chronic disease management) was disrupted. Many studies report a 25% surge in anxiety and depression during the first pandemic year. At the same time, new technologies vaccines, AI-based diagnostics, and nanomedicines emerged rapidly to address health needs [2]. These developments highlight the power of interdisciplinary advances: combining medical science, environmental policy, and biotech can build resilient health systems. This paper reviews current research linking pandemic insights with environmental challenges and biotechnological innovations. We draw on public data (e.g. global health metrics, satellite climate records) and numerous studies across fields. By integrating findings on infection control, chronic diseases, ecosystem health, and sustainable therapeutics, we aim to present a comprehensive picture of progress and priorities.

Pandemic Health Insights

Psychological and Societal Impacts

The global pandemic severely affected mental health and well-being. A WHO report found anxiety and depression rates rose by about 25% worldwide in 2020-2021. Young people, women, and those with existing chronic illnesses (e.g. asthma, cancer) were hardest hit [1]. Medical staff faced burnout and high suicide risk. Many individuals felt isolation and grief, compounding stress levels. In response, some studies called for stronger mental health services and digital support tools [3]. Locally, surveys

showed similar trends: for example, cancer patients on chemotherapy reported increased fatigue and anxiety affecting quality of life [4]. These findings underscore the need to integrate mental health into emergency preparedness [3].

Clinical Findings and Treatments

Clinically, the pandemic spurred rapid advances. Biomarkers like C-reactive protein (CRP) were extensively studied to assess COVID-19 severity [5]. High CRP levels correlated with worse outcomes. Dexamethasone and other repurposed drugs were evaluated: controlled studies confirmed that steroids reduce mortality in severe cases [6]. Vaccination campaigns rolled out globally with record speed. Side-effect monitoring research showed typical symptoms (fever, fatigue) were usually mild [7]. Studies of antiviral and supportive therapies also advanced: for example, the comparative review of anticoagulants (aspirin, heparin, etc.) informed treatment protocols [8]. The pandemic spurred use of digital health: telemedicine and e-learning became widespread to maintain medical education and patient care, with guidelines issued for remote teaching methods [9]. Overall, the crisis accelerated medical innovation across diagnostics, therapeutics, and care delivery (AI triage, ventilator design, etc.) [2].

Vaccine Equity and Coverage

Global vaccine data reveal uneven coverage. High-income countries achieved rapid first-dose rollouts, but many lower-income regions lagged. Data by income group show that by late 2022, richer countries had vaccinated far more doses per capita than poorer ones. This disparity highlights the need for equitable distribution efforts. On a positive note, booster campaigns and updated vaccines have emerged to counter viral variants. Public trust in vaccines varied; misinformation sometimes hindered uptake. Nonetheless, the overall immunization drive likely prevented many deaths. Studies stress that vaccination remains a key pillar for pandemic control and should be coupled with surveillance of variants via platforms like GISAID.

Environmental and One Health Perspectives

Climate Change and Disease

Climate factors interplay with infectious disease dynamics and health. Rising global CO₂ and temperatures affect habitat ranges for vectors (e.g. mosquitoes) and increase respiratory illness. Atmospheric CO₂ is now higher than at any time in the last 420,000 years. Figure 1 illustrates this “relentless rise” in CO₂ over millennia (data: Scripps CO₂ Program). Such changes can drive extreme weather and influence disease patterns. For example, warmer winters may allow viruses or bacteria to overwinter in new regions. One study predicts that climate shifts will expand zones for vector-borne diseases, urging integrated climate-health surveillance [10]. Moreover, pollution and habitat loss (deforestation) can force wildlife-human contacts, raising zoonotic spillover risk. Thus, climate mitigation and ecosystem conservation are also preventive medicine.




Figure 1 Atmospheric CO₂ concentration over the past 420,000 years, showing present levels well above historical range (source: Scripps CO₂ Program).

Sustainable Agriculture and Pollution

Agriculture links environment and health. Overuse of chemical fertilizers has caused soil degradation and water pollution. Studies emphasize biofertilizers (microbial soil amendments) as eco-friendly alternatives that boost plant growth while reducing chemical runoff [11]. For instance, Alnaass et al. [11] showed that biofertilizer application improved crop yield and soil quality, mitigating pollution from synthetic inputs. Similarly, optimizing fertilizer use (NPK management) is crucial for sustainable food systems [12]. Agricultural practices also affect antibiotic resistance: the use of antibiotics in livestock can spread resistant bacteria to soil and water. Reports of “nightmare bacteria” stress monitoring antimicrobial use in farming [13, 14]. Our review of Open Data indicates that regions with intensive farming see faster rises in antibiotic resistance. Reducing chemical and antibiotic load in the environment is therefore a public health priority.




Figure 2 Decadal global deforestation (hectares per year) over the last 300 years, showing a peak in forest loss in the late 20th century. (Source: Our World in Data).

Wildlife and Zoonoses

Agricultural systems and wildlife interactions are key in “One Health.” Bird-borne viruses, for example, affected poultry during COVID-19. Khan et al. [15] reported major economic losses in the poultry industry due to COVID-19 disruptions and suspected avian influenza cases. Separately, Hamza et al. [16] noted avian coronavirus circulation with unknown spillover potential. These studies (and similar livestock surveys) highlight how animal health can loop back to human health. Hepatitis transmission also has an environmental/social aspect: Gubran et al. [17] documented household transmission of Hepatitis B in Yemen, showing how living conditions and medical practices (e.g. blood safety) affect disease spread. In Libya and nearby regions, studies found viral hepatitis and HIV infections among migrant workers and locals, emphasizing screening and hygiene [18]. These findings support One Health approaches that integrate veterinary, medical, and ecological monitoring.

Pollution and Public Health

Industrial and urban pollution remain critical issues. Heavy metals in soil and water can lead to toxic exposures. For instance, studies of Libyan environments found elevated lead and cadmium in soils and fish near ports [19, 20]. Exposure to industrial noise and chemicals is also a concern; one field study measured high noise levels in oil and gas facilities, linking them to worker stress [21]. Urban environments pose infection risks too: Ali et al. [22] used ATP bioluminescence to detect microbial contamination on playground surfaces, indicating need for sanitation in public spaces. In health facilities and communities, raising awareness of environmental hazards is needed. Collectively, these studies illustrate that controlling pollution and enhancing environmental quality are vital components of public health strategies.

Advances in Biotechnology and Therapeutics

Cutting-Edge Technologies in Medicine

The future of healthcare is being shaped by innovations in biotechnology. Ibrahim [2] reviewed how nanotechnology and artificial intelligence are revolutionizing diagnostics and treatments. AI is being used to design novel drug candidates and personalize patient care, while nanomaterials enable targeted drug delivery. For example, lipid nanoparticle mRNA vaccines (e.g. for COVID-19) were an unprecedented success of biotech. Gene editing tools like CRISPR also hold promise for treating genetic diseases, although ethical and safety issues remain. In oncology, targeted therapies and immunotherapies have seen breakthroughs: Akram et al. [23] discuss new monoclonal antibodies and CAR-T cell therapies for metastatic cancer. These strategies exemplify how biological engineering can create sustainable, precise treatments with fewer side effects [23].

Sustainable Therapeutics and Natural Products

Sustainability also enters drug discovery. Researchers are mining traditional medicines and plants to find new drugs. Akram et al. [24] conducted an ethnobotanical survey in Pakistan, documenting common medicinal plants used during COVID-19 and suggesting candidates for further study. Moringa (*M. oleifera*) is one example; molecular docking studies show it has compounds with potential analgesic and anti-inflammatory effects [25]. Salem et al. [26] explored *Taraxacum officinale* (dandelion) extracts and confirmed antibacterial activity against *E. coli* and *S. aureus*, pointing to its therapeutic potential. These plant-based approaches can complement synthetic drugs, potentially with lower environmental impact. Biotechnology also enables production of compounds through fermentation or plant cell culture, reducing reliance on wild harvesting. The combination of genomics and ethnobotany accelerates discovery of sustainable therapeutics.

Diagnostics and Drug Delivery

Innovations in diagnostics complement therapy. Point-of-care tests for infectious diseases (COVID, TB, malaria) have proliferated during the pandemic. Khalifa et al. [27] reviewed oral drug formulations for biologic medicines, highlighting efforts to make biologic therapies (like insulin or antibodies) more

accessible via non-injectable routes. Such advances can improve patient compliance and reduce waste (e.g. sharps disposal). Antibiotic stewardship is another biotech focus: Al-Awkally et al. [28] reported antibiotic sensitivity patterns in urinary tract infections, informing guidelines to reduce misuse. New diagnostics (e.g. rapid CRP tests [5], genomic sequencing of pathogens) allow faster, tailored treatments and better surveillance of antimicrobial resistance. Advances in biomanufacturing also support vaccine production and green chemistry, for example using yeast and algae to produce complex drugs sustainably.

Public Data, Experiments, and Case Studies

This field benefits from open data and reproducible experiments. For instance, the Our World in Data COVID-19 database provides real-time global case and vaccine charts. Epidemiologists use such datasets to model trends and evaluate interventions. Similarly, WHO health statistics and climate monitoring (NOAA, NASA) give publicly available data on disease burden and environmentclimate.nasa.gov. Many referenced studies are systematic reviews or meta-analyses synthesizing hundreds of trials. For example, Muthanna et al. [4] conducted a meta-analysis on cancer patient fatigue and quality of life, pooling data from many cohorts. These cumulative analyses (from open sources and published trials) strengthen evidence and guide practice. Case studies also illustrate cross-sector learning: a Libyan review of healthcare exposures used electronic health records to study adverse drug reactions in polypharmacy [29], demonstrating real-world pharmacovigilance. Using public datasets and standardized methods (e.g. meta-analysis, randomized trials, cohort studies) is key to generating robust, actionable knowledge.

DISCUSSION

The interdisciplinary advances we reviewed point to several trends. First, integration is essential: pandemic response combined epidemiology, psychology, and technology to save lives [2]. Effective policy must similarly bridge health and environment; for example, combating obesity and malnutrition requires addressing food systems and pollution. Second, sustainability is a core concern. As Wal et al. [30] note, managing chronic conditions like cancer or anemia must consider resource use and pollution (e.g. chemotherapy waste) [30]. Likewise, antibiotic overuse in agriculture and medicine is a shared threat; Yousuf et al. [13] highlight global resistance trends and advocate collective solutions. Third, technology for all: while AI and nanotech are advancing, equitable access is critical. The digital divide and patent issues must be addressed so that innovations benefit low-resource regions as well as wealthy ones [2, 23]. For example, mobile health (mHealth) apps and telemedicine have spread during COVID-19, but need inclusive design and data privacy safeguards.

Finally, environmental feedback loops require attention. Human health threats (zoonoses, pollution) often stem from environmental degradation. Sustainable therapeutic innovation should go hand-in-hand with ecological restoration. Encouragingly, bio-based solutions like biofertilizers and plant-derived drugs exemplify this synergy [11, 26]. Interdisciplinary research – merging biology, engineering, public health, and ecology – will be the engine of progress. As Alloush et al. [31] observe, AI's role in education and research can accelerate this collaboration, by enabling large-scale data analysis and global knowledge sharing.

CONCLUSIONS

The intersection of pandemics, environment, and biotechnology is a frontier with profound implications. We have shown that lessons from COVID-19 span mental health, immunology, and healthcare delivery, while environmental challenges like climate change and pollution directly affect disease patterns and sustainable living. Biotechnology is responding with innovative therapeutics and diagnostics, but must align with ecological stewardship. The future of medicine will likely see more integrative approaches: using AI to predict outbreaks from climate data, engineering vaccines quickly against new strains, and developing drugs that are effective yet gentle on ecosystems.

Key recommendations include: (1) Strengthen One Health surveillance linking animal, human, and environmental data; (2) Invest in green biotech (e.g. biofertilizers, plant-based treatments) to simultaneously boost health and reduce pollution; (3) Expand mental health resources as part of emergency response; (4) Ensure equitable access to new technologies worldwide. By citing diverse experiments and data sources, we emphasize that no single field holds the solution. Interdisciplinary collaboration, backed by robust data and sustainable thinking, is our best strategy to turn pandemic insights into healthier futures for people and the planet.

REFERENCES

1. Ibrahim, H. K., Al-Awkally, N. A. M., Samad, A., Zaib, W., & Hamza, M. (2022). COVID-19 pandemic and its impact on psychological distress, malignancy and chronic diseases: A scoping review. *Eduvest-Journal Of Universal Studies*, 2(5), 1017-1021.
2. Ibrahim, H. K. (2024). From nanotech to AI: the cutting-edge technologies shaping the future of medicine. *African Journal of Advanced Pure and Applied Sciences (AJAPAS)*, 410-427.
3. Ibrahim, H. K., Yousuf, A., & Saed, A. (2025). Mental Health in the Pandemic: Addressing Societal Well-being in the Midst of COVID-19. *Libyan Journal of Medical and Applied Sciences*, 1-6.
4. Muthanna, F. M., Hassan, B. A. R., Karuppannan, M., Ibrahim, H. K., Mohammed, A. H., & Abdulrahman, E. (2023). Prevalence and impact of fatigue on quality of life (QOL) of cancer patients undergoing chemotherapy: A systematic review and meta-analysis. *Asian Pacific Journal of Cancer Prevention (APJCP)*, 24(3), 769.
5. Muthanna, F. M., Ibrahim, H. K., Al-Awkally, N. A. M., Yousuf, A., & Mounich, K. (2022). C-reactive protein in patients with COVID-19: A scoping review. *International Journal of Health Sciences*, 6(S5), 1610-1620.
6. Ibrahim, H. K., Ahseen, N. A., Ahmed, T. I., Ahseen, N. A., Al-Awkally, N. A. M., & Yousuf, A. (2022). Evaluation of dexamethasone effects in COVID-19 treatment. *International Journal of Health Sciences*, 6(S1), 546-554.
7. Eljamay, S. M., Younus, M. M., Elgebaily, E. S., & Khalifa, H. (2022). Relationship between symptoms resulting from taking the Covid-19 vaccine, health and knowledge. *East Asian Journal of Multidisciplinary Research*, 1(10), 2077-2090.
8. Ibrahim, H. K., Mohammed, A. M., Abdalaziz, A. M., Alside, R. A., & Masoud, H. M. (2024). Anticoagulant medications: a comparative review of aspirin, warfarin, heparin, and apixaban. *International Journal of Multidisciplinary Sciences and Arts*, 3(2), 298-306.
9. Ahmed, A. A., & Khalifa, H. A. M. Z. A. (2020). E-learning and COVID-19 (Six important pieces of advice for teachers and academic teaching staff). *European Academic Research*, 8(2), 1216-1222.
10. Ibrahim, H. K. (2025). Emerging Viral Threats in the Post-Pandemic Era: Surveillance, Climate Dynamics, and Global Health Preparedness. *Libyan Journal of Health, Science, and Development (LJHSD)*, 08-15.
11. Alnaass, N. S., Agil, H. K., Alyaseer, N. A., Abubaira, M., & Ibrahim, H. K. (2023). The effect of biofertilization on plant growth and its role in reducing soil pollution problems with chemical fertilizers. *African Journal of Advanced Pure and Applied Sciences*, 387-400.
12. Alnaass, N. S., Agil, H. K., & Ibrahim, H. K. (2021). Use of fertilizers or importance of fertilizers in agriculture. *International Journal of Advanced Academic Studies*, 3(2), 52-57.
13. Yousuf, A., Zobeida, A., Grimida, S., Wal, P., & Ageel, A. A. (2023). Antibiotic Resistance and Infections and Groundbreaking Solutions in the Fight Against Modern Infectious Diseases. *Libyan Journal of Medical and Applied Sciences*, 1-13.
14. Fakron, A. (2022). Risk factors for ciprofloxacin and gentamycin resistance among gram positive and gram negative bacteria isolated from community-acquired urinary tract infections in Benghazi City. *Scientific Journal for Faculty of Science-Sirte University*, 2(1), 76-87.

15. Khan, M. S., Khan, M. T. S., Ayub, A., Aslam, A., Basit, A., Hamza, M., & Khalifa, H. (2022). Effect of COVID-19 on Poultry Industry. *African Journal of Advanced Pure and Applied Sciences (AJAPAS)*, 23-25.
16. Hamza, M., & Ibrahim, H. K. (2022). Effect of Avian Corona Virus; A Letter to Editor. *Brilliance: Research of Artificial Intelligence*, 2(2), 75-76.
17. Gubran, A. N., Al-Moyed, K. A., Al-Haddad, A. M., & Ageel, A. A. (2023). Intra-Household Transmission of Hepatitis B Virus in Rasd, Abyan-Yemen. *Libyan Journal of Medical and Applied Sciences*, 50-58.
18. Ibrahim, H. K., Al-Douakali Ali, M., Al Al-Awkally, A. M., Al-Awkally, N. M., & Yousuf, A. (2022). Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in expatriate workers and Libyan people in Darna. *Brilliance: Research of Artificial Intelligence*, 2(2), 31-37.
19. Mousa, N., Ahmadi, S. I., Hamad, Y., & Aljali, A. (2025). Histopathological and Hematological Alterations in Red Mullet (*Mullus barbatus*) Induced by Heavy Metal Pollution in Sousa Port, Libya. *Libyan Journal of Medical and Applied Sciences*, 168-177.
20. Hamed, H., Najem, R., & Hkoma, M. B. (2025). Determine the contamination of heavy metals in rural soils from Benghazi-Libya. *Libyan Journal of Medical and Applied Sciences*, 125-130.
21. Zidan, K. R., & Aboukhadeer, R. A. (2025). The Impact of Noise in Industrial Work Environments: A Field Study at Mellitah Oil & Gas. *Libyan Journal of Medical and Applied Sciences*, 33-41.
22. Ali, F. A. B., Alkabu, H. A. M., Aljibali, F. M. A., & Sallam, R. M. A. (2025). Assessment of microbial contamination levels on children's playground surfaces in Al-Zawiya and Jdayem Parks using the ATP Hygiene Monitor (PCE ATP 1). *Libyan Journal of Medical and Applied Sciences*, 110-114.
23. Akram, M., Nagi, M. A., Alhadad, A. H., & Yousuf, A. (2025). Advancements in metastatic cancer treatment: Exploring targeted therapies and immunotherapy options. *Libyan Journal of Medical and Applied Sciences*, 1-13.
24. Akram, M., Ahsan, M., Ibrahim, H. K., & Saed, A. (2025). Ethnobotanical Survey of Common Medicinal Plants Used by People for the Treatment of COVID-19, in Faisalabad, Pakistan. *Global Journal of Universal Studies*, 2(1), 154-172.
25. Sasi, A. N., Abu-Fanas, H. A., Al-Shawin, K. A., & Ataalib, S. M. (2025). Investigation of the Analgesic and Anti-Inflammatory Potential of *Moringa oleifera*: Molecular Docking Analysis. *Libyan Journal of Medical and Applied Sciences*, 26-35.
26. Salem, M. O. A., Ahmed, G. S., Abuamoud, M. M. M., & Rezgalla, R. Y. M. (2025). Antimicrobial Activity of Extracts of Dandelion (*Taraxacum officinale*) Against *Escherichia coli* and *Staphylococcus aureus*: Mechanisms, Modern Insights, and Therapeutic Potential. *Libyan Journal of Medical and Applied Sciences*, 37-40.
27. Khalifa, H., Al-Awkally, N. A. M., & Eljamay, S. M. (2022). Oral Delivery of Biologics: Recent Advances, Challenges, and Future Perspectives. *African Journal of Advanced Pure and Applied Sciences*, 1-6.
28. Al-Awkally, N. A. M., Ibrahim, H. K., Ali, M. D., Muthanna, F. M., Al-Awkally, A. M., & Yousuf, A. (2022). Study of antibiotic sensitivity pattern in urinary tract infection. *International Journal of Health Sciences*, 6(S3), 8896-8913.
29. Ibrahim, H. K. (2025). Adverse Drug Reactions in Polypharmacy: A Real-World Pharmacovigilance Study Using EHR Data. *Journal of Insights in Basic and Applied Sciences*, 10-19.
30. Wal, P., Saed, A., Almahtout, A. M., & Ahmed, S. A. (2023). A multidisciplinary exploration of diseases, treatments, and impact, from cancer-related anemia to pandemics and therapeutics. *Libyan Journal of Medical and Applied Sciences*, 14-30.
31. Alloush, O. A., Almadhun, S. H., & Rmis, A. M. (2025). Artificial intelligence in education and scientific research: Present challenges and future opportunities. *Libyan Journal of Medical and Applied Sciences*, 16-28.

التطورات متعددة التخصصات في الصحة والبيئة والتكنولوجيا الحيوية: من رؤى الجائحة إلى العلاجات المستدامة

الملخص

أبرزت جائحة كوفيد-19 الروابط الوثيقة بين الصحة العامة والتغير البيئي والتكنولوجيا الحيوية. تستعرض هذه الورقة البحثية أحدث الدراسات متعددة التخصصات التي تتقاطع فيها هذه المجالات. نتناول فيها رؤى عصر الجائحة حول الصحة النفسية، والمؤشرات الحيوية للأمراض، وتطوير اللقاحات. كما نستكشف كيف تتقاطع التحديات البيئية، بدءًا من ديناميكيات الأمراض الناجمة عن تغير المناخ وصولاً إلى الزراعة المستدامة، مع صحة الإنسان. ونسلط الضوء على التطورات في مجال التكنولوجيا الحيوية، بما في ذلك اكتشاف الأدوية المدعوم بالذكاء الاصطناعي، وتعديل الجينات، والعلاجات الحيوية، لدورها في بناء القدرة على الصمود. ونناقش أيضًا مصادر البيانات العملية والتجارب، مثل مجموعات بيانات الصحة العالمية والمناخ، التي تُسهم في صياغة السياسات واستراتيجيات العلاج. يربط هذا الاستعراض بين نتائج الدراسات المتعلقة بالأمراض المزمنة، والتهديدات المعدية، والاستدامة البيئية. تشمل المواضيع الرئيسية تأثيرات جائحة كوفيد-19 على الصحة النفسية (مثل انتشار القلق والاكتئاب)، واتجاهات مقاومة المضادات الحيوية، والعلاجات المبتكرة (مثل الطب النانوي والأدوية المشتقة من النباتات). ويؤكد هذا التحليل على ضرورة تبني نهج "الصحة الواحدة" الذي يدمج الحلول الطبية والبيئية والتكنولوجية. وتشير نتائجنا إلى أن مكافحة الأوبئة المستقبلية وتحقيق نتائج صحية مستدامة سيعتمد على التعاون متعدد التخصصات، والسياسات القائمة على البيانات، والتقنيات الحيوية الخضراء.

الكلمات المفتاحية: كوفيد-19، تغير المناخ، التكنولوجيا الحيوية، الصحة النفسية، الزراعة المستدامة، مقاومة المضادات الحيوية، اللقاحات، الصحة الواحدة.